within Pharmacolibrary.Drugs.ATC.L;

model L01FX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 2.92 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 28 / 1000000,
    adminCount     = 1,
    Vd             = 0.00435,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Blinatumomab is a bispecific T-cell engager (BiTE) monoclonal antibody used in the treatment of acute lymphoblastic leukemia (ALL). It binds CD19 on B-cells and CD3 on T-cells, directing cytotoxic T-cells to kill malignant B-cells. Blinatumomab is approved for the treatment of relapsed or refractory B-cell precursor ALL in adults and children.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults (18–77 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia treated with intravenous blinatumomab. Parameters obtained at steady-state during continuous intravenous infusion.</p><h4>References</h4><ol><li><p>Zhu, M, et al., &amp; Doshi, S (2016). Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. <i>Clinical pharmacokinetics</i> 55(10) 1271–1288. DOI:<a href=&quot;https://doi.org/10.1007/s40262-016-0405-4&quot;>10.1007/s40262-016-0405-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27209293/&quot;>https://pubmed.ncbi.nlm.nih.gov/27209293</a></p></li><li><p>von Stackelberg, A, et al., &amp; Gore, L (2016). Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 34(36) 4381–4389. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2016.67.3301&quot;>10.1200/JCO.2016.67.3301</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27998223/&quot;>https://pubmed.ncbi.nlm.nih.gov/27998223</a></p></li><li><p>Clements, JD, et al., &amp; Doshi, S (2020). Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. <i>Clinical pharmacokinetics</i> 59(4) 463–474. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00823-8&quot;>10.1007/s40262-019-00823-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31679130/&quot;>https://pubmed.ncbi.nlm.nih.gov/31679130</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FX07;
